Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2012-08-08 Earnings Release
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Earnings Release 2012
Earnings Release Classification · 99% confidence The document text contains a review of '1H/2012 figures', discusses revenues, operating income, liquidity, and confirms the '2012 financial guidance'. It includes detailed historical and estimated financial tables (Revenues, EBITDA, EBIT, margins) and a table showing updated estimates for 2012E, 2013E, and 2014E. The content is clearly focused on summarizing and analyzing periodic financial performance, which aligns with an Interim/Quarterly Report (IR) or potentially an Earnings Release (ER). However, the depth of the financial tables, the inclusion of detailed forecasts, and the context of a research report analyzing the results strongly suggest this is a summary or analysis of a comprehensive periodic report, rather than just the initial press release (ER). Since it covers the first half (1H/2012), it fits the definition of an Interim/Quarterly Report (IR) analysis. Given the structure, it is most likely an analyst's report based on the company's official 1H report, but the core subject matter is the interim financial results. H2 2012
2012-08-08 English
Evotec to Report First Half Year 2012 Results on 8 August 2012
Report Publication Announcement Classification · 99% confidence The document is a short news release dated August 2, 2012, announcing that Evotec AG 'will report its financial results for the first half of 2012 on Wednesday, 8 August 2012.' It provides details for an upcoming conference call and webcast to discuss these results. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the future publication of results, rather than containing the results themselves, should be classified as a Report Publication Announcement (RPA). This announcement is specifically about the publication date and associated call for the 'first half year 2012 results,' which would typically be an Interim/Quarterly Report (IR). Therefore, the announcement of the report's release date fits the RPA definition best.
2012-08-02 English
Regulatory Filings 2012
Regulatory Filings Classification · 85% confidence The document is a research publication from DZ BANK AG regarding the company Evotec. It contains financial analysis, investment ratings, and forward-looking estimates (KGV, EV/EBITDA, etc.). It is not an official company filing (like a 10-K or IR) but rather an external analyst report. Since the provided categories do not include 'Analyst Report' or 'Research Note', and it does not fit the criteria for official corporate filings, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous documents. FY 2012
2012-07-12 German
Evotec AG: CureBeta, a collaboration between Evotec and Harvard University enters strategic alliance with Janssen Pharmaceuticals
Regulatory Filings Classification · 100% confidence The document is a press release dated July 10, 2012, announcing a license and collaboration agreement between Evotec AG and Janssen Pharmaceuticals regarding the CureBeta program. It details financial terms (upfront payment, milestones, royalties) and includes quotes from executives and a mention of an upcoming conference call to discuss the news. This type of announcement, detailing a significant business development (licensing deal) and providing key financial highlights without being a full periodic report (like 10-K or IR), fits best under the 'Earnings Release' (ER) category if it were quarterly results, but since it is a specific corporate event announcement that doesn't fit other specific categories like M&A (TAR) or Capital Change (CAP), it is most appropriately classified as a general corporate announcement. Given the options, and since it is a news release detailing a major business event, it is often categorized as an Earnings Release (ER) if it contains key financial metrics, or Regulatory Filing (RNS) if it's a general announcement. However, since it is a detailed announcement of a significant business transaction and includes financial figures, it is more specific than a generic RNS. It is not a transcript (CT), a presentation (IP), or a formal regulatory filing like a 10-K. Since it is a news release announcing a major corporate event with financial details, and there isn't a specific 'Business Development Announcement' code, 'ER' (Earnings Release) is often used broadly for significant financial news releases, but 'RNS' (Regulatory Filings) is the safest fallback for non-standard, material news disseminated via a news service (DGAP). Given the structure and content (a news detail announcement), RNS is the most appropriate general category for material, non-periodic corporate news that doesn't fit the other specific codes.
2012-07-10 English
CureBeta, a collaboration between Evotec AG and Harvard University enters strategic alliance with Janssen Pharmaceuticals
Capital/Financing Update Classification · 98% confidence The document is an 'Ad-hoc' announcement dated July 10, 2012, detailing a 'license and collaboration agreement' between Evotec AG and Janssen Pharmaceuticals, including upfront payments, potential milestone payments, and royalties. This content directly relates to a significant financing or strategic partnership activity, which falls under the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but specifically concerns a major financial/contractual arrangement.
2012-07-10 English
Telefonkonferenz zur Lizenzvereinbarung mit Janssen Pharmaceuticals, Inc.
Investor Presentation Classification · 98% confidence The document text contains a title referencing 'Analyst information' and a date ('2012'), followed by sections like 'Forward-looking statements', 'Agenda', and detailed slides summarizing a collaboration ('Cure*Beta* Alliance with Janssen'). The structure, use of bullet points, summary tables, and quotes from key personnel (CSO, Global Therapeutic Head) strongly indicate this is a presentation deck prepared for an external audience, likely analysts or investors, detailing scientific progress and strategic partnerships. This aligns best with the Investor Presentation (IP) category, which covers detailed presentations on financials, strategy, and market position, rather than a formal regulatory filing (like 10-K or ER) or a transcript.
2012-07-10 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.